Every 10-Q that Evolent Health, Inc (EVH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EVH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVH filings page.
Evolent Health, Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Revenue for the quarter rose to $652.5 million from $444.3 million a year earlier, and six-month revenue increased to $1.15 billion from $928.0 million. The company posted a quarterly operating loss of $9.6 million and a net loss attributable to common shareholders of $28.4 million, versus a $51.1 million loss in the prior-year quarter, or $(0.25) basic and diluted loss per share. For the first half of 2026, the net loss narrowed to $55.0 million, or $(0.49) per share, compared with $123.3 million in the first half of 2025.
As of June 30, 2026, Evolent held $115.7 million in cash and cash equivalents and total cash plus restricted cash of $141.5 million, against $966.5 million of long-term debt and a $108.9 million tax receivables agreement liability. Reserves for claims and performance-based arrangements increased to $378.4 million from $192.2 million at year-end, reflecting higher risk-sharing activity. Intangible assets, net, were $554.4 million and goodwill was $694.4 million following a previously recorded $398.0 million goodwill impairment in 2025. Total shareholders’ equity declined to $383.2 million, and Class A common shares outstanding were 113,059,335 as of August 1, 2026.
Evolent Health, Inc. reported first-quarter 2026 revenue of $496.2 million, slightly above $483.6 million a year earlier, reflecting growth across Medicaid, Medicare and commercial lines. The company recorded an operating loss of $10.6 million and a net loss of $26.6 million, a marked improvement from a $72.3 million loss a year ago, with loss per share narrowing to $0.24 from $0.63. Cash and restricted cash totaled $168.7 million, while long-term debt stood at $973.5 million, plus substantial term loans and revolving borrowings under its credit facilities. Management states current liquidity, including $142.0 million of unrestricted cash, is sufficient to cover at least the next twelve months. Reserves for claims and performance-based arrangements rose to $232.0 million, highlighting the scale of risk-sharing contracts in its value-based care model.
Evolent Health (EVH) reported third‑quarter 2025 results with revenue of $479.5 million, down from $621.4 million a year ago. Operating performance improved to a small operating income of $0.9 million versus a prior loss, but the company recorded a net loss of $26.9 million (basic and diluted loss per share $0.24).
On the balance sheet, cash and cash equivalents were $116.7 million and restricted cash was $26.4 million. Long‑term debt rose to $1.05 billion while short‑term debt declined, reflecting refinancing and the exchange of Series A Preferred Stock into a second‑lien term loan; mezzanine equity was removed. The company signed an agreement to sell Evolent Care Partners Holding Company for $100.0 million, plus up to $13.0 million contingent consideration, reclassifying $89.7 million of net assets (including allocated goodwill) to held for sale. For the nine months, operating cash flow was $(10.0) million, influenced by changes in reserves and working capital.
Evolent reported weaker second-quarter results with revenue of $444,328 thousand, down from $647,145 thousand a year earlier, and a net loss attributable to common shareholders of $51,090 thousand, or $0.44 per share, for the three months ended June 30, 2025. Operating expenses slightly exceeded revenue, producing a small operating loss, while interest expense rose versus the prior year and a $52,544 thousand loss on option exercise impacted six-month results.
On the balance sheet, the company held $150,995 thousand of cash and cash equivalents (total cash and restricted cash $177,970 thousand) and states it believes it has sufficient liquidity for at least the next twelve months. Total assets declined to $2,461,532 thousand from $2,544,411 thousand, long-term debt increased to $648,455 thousand from $490,520 thousand, and shareholders' equity fell to $896,005 thousand from $1,001,259 thousand. Operating cash used $25,769 thousand for the six months ended June 30, 2025, while financing provided $98,927 thousand, including $221,000 thousand of long-term debt proceeds.